Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.

Details

Serval ID
serval:BIB_0DB753CF82DB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Journal
Cancer immunology, immunotherapy
Author(s)
Budczies J., Kirchner M., Kluck K., Kazdal D., Glade J., Allgäuer M., Kriegsmann M., Heußel C.P., Herth F.J., Winter H., Meister M., Muley T., Goldmann T., Fröhling S., Wermke M., Waller C.F., Tufman A., Reck M., Peters S., Schirmacher P., Thomas M., Christopoulos P., Stenzinger A.
ISSN
1432-0851 (Electronic)
ISSN-L
0340-7004
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incompletely understood.
We performed comparative mRNA expression profiling of 31 ALK-positive, 40 EGFR-positive and 43 ALK/EGFR-negative lung ADC focused on immune gene expression. The presence and levels of tumor infiltration lymphocytes (TILs) as well as fourteen specific immune cell populations were estimated from the gene expression profiles.
While total TILs were not lower in ALK-positive and EGFR-positive tumors compared to ALK/EGFR-negative tumors, specific immunosuppressive characteristics were detected in both subgroups: In ALK-positive tumors, regulatory T cells were significantly higher compared to EGFR-positive (fold change: FC = 1.9, p = 0.0013) and ALK/EGFR-negative tumors (FC = 2.1, p = 0.00047). In EGFR-positive tumors, cytotoxic cells were significantly lower compared to ALK-positive (FC = - 1.7, p = 0.016) and to ALK/EGFR-negative tumors (FC = - 2.1, p = 2.0E-05). A total number of 289 genes, 40 part of cytokine-cytokine receptor signaling, were differentially expressed between the three subgroups. Among the latter, five genes were differently expressed in both ALK-positive and EGFR-positive tumors, while twelve genes showed differential expression solely in ALK-positive tumors and eleven genes solely in EGFR-positive tumors.
Targeted gene expression profiling is a promising tool to read out tumor microenvironment characteristics from routine diagnostic lung cancer biopsies. Significant immune reactivity including specific immunosuppressive characteristics in ALK- and EGFR-positive lung ADC, but not a total absence of immune infiltration supports further clinical evaluation of immune-modulators as partners of ICB in such tumors.
Keywords
ALK fusion, EGFR mutation, Immune checkpoint blockade, Immunosuppression, Immunotherapy, Lung adenocarcinoma
Pubmed
Web of science
Open Access
Yes
Create date
25/06/2021 16:39
Last modification date
19/11/2021 6:40
Usage data